Psoriatic Arthritis

1. Topic Overview

Summary

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that develops in approximately 20-30% of patients with psoriasis, representing a prevalence of 0.3-1% in the general population. [1,2] It belongs to the spondyloarthropathy family and is characterised by seronegativity (rheumatoid factor negative). The disease presents with diverse clinical patterns ranging from oligoarticular involvement to destructive polyarthritis, with hallmark features including dactylitis ("sausage digit"), enthesitis, nail dystrophy, and axial involvement. [3] Early recognition and treatment with disease-modifying antirheumatic drugs (DMARDs) or biologics targeting key inflammatory cytokines (TNF-α, IL-17, IL-23) can prevent irreversible joint damage and disability. [4,5]

Key Facts

• Definition: Inflammatory arthritis associated with psoriasis; classified as seronegative spondyloarthropathy
• Prevalence: Affects 19.7% (95% CI: 18.5-20.9%) of psoriasis patients; 0.3-1% of general population [2]
• Incidence: 0.27-2.7 per 100 person-years among psoriasis patients [2]
• Characteristic Features: Dactylitis (30-50%), enthesitis (40%), nail changes (80%), axial involvement (40%) [3]
• Arthritis Patterns: 5 subtypes (Moll & Wright classification) with oligoarticular pattern most common (60-70%) [6]
• Key Imaging: "Pencil-in-cup" deformity, periostitis, new bone formation, asymmetric sacroiliitis [3]
• Treatment Goal: Achieve minimal disease activity (MDA) or remission to prevent irreversible structural damage [7]
• Prognosis: Up to 47% develop erosive disease within 2 years without treatment; biologics can prevent progression [8]

Clinical Pearls

CASPAR Criteria Gold Standard: Diagnosis requires established inflammatory arthritis (peripheral, spinal, or entheseal) PLUS ≥3 points from: current psoriasis (2), history of psoriasis (1), family history of psoriasis (1), nail dystrophy (1), dactylitis (1), RF negative (1), or juxta-articular new bone formation (1). Sensitivity 91%, Specificity 99%. [9]

Nails Tell the Story: Nail involvement (pitting, onycholysis, hyperkeratosis) is present in up to 80% of PsA patients vs. 40% of psoriasis patients without arthritis — it's a strong predictor of joint disease and should prompt screening. [10]

Skin Before Joints — Usually: In 68% of cases, psoriasis precedes arthritis by a mean of 7-12 years. However, 15-20% present with arthritis first ("arthritis sine psoriasis") — always check family history and examine hidden psoriasis areas (scalp, navel, natal cleft, ears). [1,3]

IL-23/IL-17 Axis is Central: The pathogenesis of PsA is driven by IL-23-induced differentiation of Th17 cells, which produce IL-17A/F. This axis drives both skin and joint inflammation, explaining the efficacy of IL-17 and IL-23 inhibitors. [11,12]

Not a Benign Disease: Contrary to historical belief, PsA is NOT a mild arthritis. Up to 47% develop erosive disease within 2 years, and 20% have severe destructive arthritis. Early aggressive treatment is essential. [8,13]

Why This Matters Clinically

Psoriatic arthritis represents a major cause of disability in patients with psoriasis, with profound impacts on quality of life, work capacity, and long-term joint integrity. [14] Unlike rheumatoid arthritis, PsA has distinct features including enthesitis (inflammation at tendon insertions) and characteristic imaging findings such as new bone formation alongside erosions. [3] The disease is associated with significant comorbidities including cardiovascular disease, metabolic syndrome, depression, and inflammatory bowel disease. [15,16] Modern biologic therapies targeting TNF-α, IL-17, and IL-23 have revolutionized treatment, achieving minimal disease activity in 50-60% of patients and preventing structural damage when initiated early. [4,5,17] Recognition of PsA among primary care physicians and dermatologists is crucial, as delayed diagnosis and treatment lead to irreversible joint destruction and functional impairment. [8]

---

2. Epidemiology

Incidence & Prevalence

• PsA Prevalence in Psoriasis: Systematic review of 266 studies (976,408 patients) found pooled prevalence of 19.7% (95% CI: 18.5-20.9%) [2]
• PsA Prevalence in General Population: 0.3-1.0%, varying by geographic region and diagnostic criteria [1,3]
• Psoriasis Prevalence: 2-3% of general population worldwide [18]
• Incidence of PsA: Ranges from 0.27 to 2.7 per 100 person-years among psoriasis patients [2]
• Pediatric PsA: Pooled prevalence of 3.3% (95% CI: 2.1-4.9%) in children and adolescents with psoriasis [2]
• Trend: Increasing recognition and diagnosis with improved awareness and CASPAR criteria implementation [9]

Geographic Variation

Demographics

Risk Factors

Non-Modifiable:

Modifiable:

Protective Factors:

• No consistent protective factors identified
• Weight loss may improve disease activity and treatment response [19]

---

3. Pathophysiology

Molecular Pathogenesis

Step 1: Genetic Susceptibility

Multiple genetic loci confer susceptibility to PsA: [11,20]

• HLA Class I: HLA-B27, B08, B38, B39 (axial disease); HLA-Cw*06:02 (psoriasis)
• Non-HLA genes: IL23R, IL12B, TNFAIP3, TRAF3IP2, ERAP1, IL23A
• These genes regulate innate immunity, antigen presentation, and IL-23/IL-17 axis

Step 2: Environmental Triggers

Environmental factors trigger disease in genetically susceptible individuals: [1,18]

• Mechanical stress/trauma (Koebner phenomenon at entheses)
• Infections (particularly streptococcal pharyngitis)
• Psychological stress
• Obesity and metabolic factors
• Skin injury

Step 3: Innate Immune Activation

Initial inflammation involves innate immune cells: [11,12]

• Dendritic cells activated by DAMPs (damage-associated molecular patterns)
• Macrophages produce TNF-α, IL-1β, IL-6
• Neutrophils infiltrate skin and synovium
• Natural killer cells and innate lymphoid cells (ILC3) produce IL-17, IL-22

Step 4: IL-23/IL-17 Axis Activation

Central pathogenic pathway in PsA: [11,12,21]

• Dendritic cells produce IL-23 (heterodimer of IL-23p19 and IL-12/23p40)
• IL-23 drives differentiation and expansion of Th17 cells
• Th17 cells produce IL-17A, IL-17F, IL-22, TNF-α, GM-CSF
• Other IL-17 sources: γδ T cells, mast cells, ILC3, αβ T cells in synovium and skin

Step 5: Tissue-Specific Inflammation

IL-17A and TNF-α act on multiple cell types: [11,12,21]

In Synovium:

• Synovial fibroblasts: Produce IL-6, IL-8, MMPs, RANKL
• Endothelial cells: Express adhesion molecules, promote leukocyte recruitment
• Osteoclasts: RANKL-driven bone resorption → erosions
• Pannus formation and cartilage destruction

In Entheses (Hallmark of SpA):

• Entheseal inflammation at tendon/ligament insertions
• IL-17 and IL-23 highly expressed at entheses [11]
• Micro-trauma triggers local inflammation
• New bone formation (enthesophytes) via IL-17-induced osteoproliferation

In Skin (Psoriasis):

• Keratinocytes: IL-17A induces hyperproliferation, LL-37, β-defensins, S100 proteins
• Creates positive feedback loop of inflammation
• Epidermal hyperplasia and parakeratosis

In Bone:

• Paradoxical erosions AND new bone formation (unique to SpA) [3]
• Erosions: RANKL-mediated osteoclast activation
• New bone: Wnt signaling, BMP pathway activation by IL-17 and mechanical stress
• Results in "pencil-in-cup" deformity, periostitis, syndesmophytes

Step 6: Structural Damage

Unchecked inflammation leads to: [3,8]

• Joint erosions and cartilage loss (47% at 2 years without treatment) [8]
• Characteristic "pencil-in-cup" deformity (phalangeal tuft erosion, metacarpal head widening)
• Ankylosis in severe cases (arthritis mutilans, less than 5%)
• Axial involvement: Asymmetric syndesmophytes, sacroiliitis
• Dactylitis: Combined flexor tenosynovitis and adjacent joint synovitis

Classification (Moll & Wright Patterns)

Historical classification (1973), still clinically useful: [6]

Note: Many patients have overlapping patterns or evolve from oligoarticular to polyarticular over time. [1]

Anatomical Considerations

Entheses:

• Primary anatomical target in spondyloarthropathies [3]
• Common sites: Achilles insertion, plantar fascia, patellar tendon, epicondyles, greater trochanters
• Inflammation at tendon/ligament insertions causes pain, swelling, and functional impairment
• Imaging: Ultrasound and MRI show entheseal thickening, vascularity, erosions, new bone

Dactylitis:

• "Sausage digit" — pathognomonic for spondyloarthropathies [3]
• Mechanism: Combined flexor tenosynovitis + synovitis of adjacent joints + soft tissue edema
• Present in 30-50% of PsA patients
• Poor prognostic factor (predicts progression to polyarticular disease) [8]
• Imaging: MRI shows diffuse soft tissue inflammation, tenosynovitis, joint effusion

Axial Skeleton:

• Sacroiliitis: Often asymmetric (unlike ankylosing spondylitis) [3]
• Spondylitis: Asymmetric, "chunky" syndesmophytes (vs. delicate bamboo spine in AS)
• Usually less severe than ankylosing spondylitis
• 40% have axial symptoms; 25-70% have radiographic sacroiliitis [3]

Eyes:

• Anterior uveitis occurs in 7-25% [22]
• More common with HLA-B27 positivity
• Presents as red, painful eye with photophobia
• Requires urgent ophthalmology referral

Nails:

• Nail matrix involvement produces pitting [10]
• Nail bed involvement produces onycholysis, subungual hyperkeratosis, "oil drop" discoloration
• 80% of PsA patients vs. 40% of psoriasis-only patients [10]
• Reflects proximity to DIP joint; anatomical link between nail and DIP enthesis

---

4. Clinical Presentation

Symptoms

Typical Presentation (Classical PsA):

Atypical Presentations:

• Arthritis sine psoriasis (15-20%): Arthritis precedes skin disease or no skin disease [1,3]

  • Must rely on CASPAR criteria (family history of psoriasis, nail dystrophy, dactylitis, new bone formation)
  • Consider in seronegative oligoarthritis with enthesitis or dactylitis

• Monoarthritis at onset: Single joint involvement (knee most common)

  • Must exclude septic arthritis, crystal arthropathy, other causes

• Isolated enthesitis: Achilles tendinitis or plantar fasciitis as sole manifestation

  • May precede arthritis by months to years

• Pediatric presentation: Oligoarticular pattern most common; high prevalence of uveitis screening needed [2]

Temporal Relationship (Skin vs. Joints):

• Skin precedes arthritis (68%): Mean interval 7-12 years [1]
• Simultaneous onset (12%)
• Arthritis precedes skin (15-20%): Diagnosis challenging; look for family history, nail changes

Signs

Musculoskeletal Examination:

• Dactylitis: Diffuse swelling of entire digit (finger or toe); "sausage digit" appearance

  • Tender to palpation along flexor tendon sheath
  • Restricted range of motion
  • "Hallmark feature: sensitivity 49%, specificity 96% for PsA [9]"

• Enthesitis: Tenderness at tendon/ligament insertions

  • "Common sites: Achilles (posterior heel), plantar fascia (inferior heel), patellar tendon, epicondyles, iliac crests"
  • May have associated swelling
  • Resistance to movement increases pain

• Joint swelling: Variable pattern

  • "Early: Often asymmetric, oligoarticular"
  • "Late: May become symmetric polyarticular (RA-like)"
  • DIP involvement common (uncommon in RA)

• Nail changes: [10]

  • Pitting (small indentations in nail plate)
  • Onycholysis (nail separation from nail bed)
  • Subungual hyperkeratosis (scaling under nail)
  • "Oil drop" sign (yellow-red discoloration)
  • Nail dystrophy (thickened, crumbling nails)

• Axial signs:

  • Reduced spinal mobility (Schober's test less than 5 cm expansion; normal ≥5 cm)
  • Reduced chest expansion (less than 5 cm; normal > 5 cm)
  • Sacroiliac joint tenderness (FABER test, Gaenslen's test)

Dermatologic Examination:

• Psoriatic plaques: Well-demarcated, erythematous, scaly plaques

  • "Must examine hidden sites: scalp, ears, umbilicus, natal cleft, genitals"
  • Scalp and intergluteal psoriasis associated with higher PsA risk [1]

• Psoriasis subtypes:

  • Plaque psoriasis (most common, 80-90%)
  • Guttate psoriasis (droplet-like, post-streptococcal)
  • Inverse psoriasis (flexural areas)
  • Pustular psoriasis (rare, severe)
  • Erythrodermic psoriasis (rare, severe)

Extra-articular Manifestations:

Red Flags

[!CAUTION] Red Flags — Seek urgent specialist review if:

• Arthritis mutilans: Severe telescoping/opera-glass deformity of digits (indicates aggressive erosive disease requiring urgent biologic therapy)
• Rapidly progressive joint destruction: Serial X-rays showing rapid erosive changes over weeks to months
• Acute uveitis: Red, painful eye with photophobia and blurred vision (ophthalmology emergency; can cause permanent vision loss)
• High fever with arthritis: Exclude septic arthritis, reactive arthritis, or systemic infection
• Neurological symptoms with axial disease: Cervical spine involvement with myelopathy or cauda equina syndrome (rare but serious)
• Erythrodermic or pustular psoriasis: Severe systemic psoriasis variants requiring urgent dermatology/rheumatology

---

5. Clinical Examination

Structured Approach

General Inspection:

• Observe gait for antalgic pattern, stiffness, or reduced spinal mobility
• Assess posture for loss of lumbar lordosis, thoracic kyphosis (axial involvement)
• Overall disease activity: cachexia, systemic unwellness

Dermatologic Examination (Essential):

• Scalp: Lift hair to examine for plaques (common, easily missed)
• Ears: Behind and in concha
• Face: Eyebrows, nasolabial folds
• Trunk: Check umbilicus, natal cleft, genitals
• Extremities: Elbows (extensor surfaces), knees, hands, feet
• Nails: All 20 nails for pitting, onycholysis, hyperkeratosis, "oil drop" sign [10]

Joint Examination (Systematic):

Perform 66/68 joint count for tender/swollen joints: [7]

• Hands: MCPs, PIPs, DIPs (key - often involved in PsA), wrists

  • Look for asymmetry
  • Assess for dactylitis (entire digit swelling)
  • Compare with RA (spares DIPs, symmetric)

• Feet: MTPs, PIPs, ankles

  • Dactylitis of toes common
  • Check for pes planus (flat feet from chronic inflammation)

• Large joints: Shoulders, elbows, hips, knees

  • Oligoarticular pattern may involve only 1-2 large joints

• Axial skeleton:

  • Inspect spinal curves
  • Palpate for sacroiliac tenderness
  • Perform Schober's test, chest expansion

Enthesis Examination:

Use validated indices (e.g., Leeds Enthesitis Index, SPARCC): [3]

Dactylitis Assessment:

• Inspect all digits (fingers and toes)
• Compare sides for asymmetry
• Palpate along flexor tendons for diffuse swelling
• Assess active and passive range of motion (restricted in dactylitis)
• Quantify: Number of digits affected (0-20 score)

Special Tests

Disease Activity Measures

Validated Instruments for PsA:

• DAPSA (Disease Activity in PSoriatic Arthritis): [7]

  • 66/68 tender + swollen joint counts + patient pain VAS + patient global VAS + CRP
  • "Remission: ≤4; Low: > 4 and ≤14; Moderate: > 14 and ≤28; High: > 28"

• MDA (Minimal Disease Activity): [23]

  • "Composite; patient achieves ≥5/7 criteria:"
    • Tender joint count ≤1
    • Swollen joint count ≤1
    • PASI ≤1 or BSA ≤3%
    • Patient pain VAS ≤15 mm
    • Patient global VAS ≤20 mm
    • HAQ ≤0.5
    • Tender entheseal points ≤1

• PASDAS (Psoriatic Arthritis Disease Activity Score): Weighted composite

Functional Assessment:

• HAQ-DI (Health Assessment Questionnaire-Disability Index): 0-3 scale; assesses ADLs

---

6. Investigations

First-Line (Bedside/Clinical)

• Complete skin and nail examination (diagnostic)
• Full joint assessment using 66/68 tender/swollen joint count
• Enthesitis count (Leeds or SPARCC index)
• Dactylitis count (0-20)

Laboratory Tests

Note: PsA is a clinical diagnosis supported by imaging and CASPAR criteria. No single laboratory test is diagnostic. [9]

Imaging

Plain Radiography:

Ultrasonography (MSUS - Musculoskeletal Ultrasound):

• Synovitis: Hypoechoic joint effusion, synovial thickening, power Doppler signal (active inflammation)
• Enthesitis: Hypoechoic thickening at insertion, increased vascularity (power Doppler), erosions, enthesophytes
• Dactylitis: Flexor tenosynovitis, joint synovitis, soft tissue edema
• Advantages: Dynamic, real-time, no radiation, detects subclinical inflammation [3]
• Utility: Diagnosis, monitoring treatment response, guiding injections

Magnetic Resonance Imaging (MRI):

• Indications: Early disease, axial involvement, assess disease activity pre-biologic
• Findings:
  • "Active inflammation: Bone marrow edema (STIR/T2 high signal), synovitis, enthesitis, soft tissue edema"
  • "Structural damage: Erosions, ankylosis, fat metaplasia (chronic inflammation)"
  • "Sacroiliitis: Bone marrow edema in subchondral bone (active); erosions, sclerosis, ankylosis (chronic) [3]"
• Scoring: SPARCC (Spondyloarthritis Research Consortium of Canada) for SI joints and spine

Computed Tomography (CT):

• Rarely used; reserved for detailed bony assessment (erosions, new bone formation) when MRI contraindicated
• Superior to X-ray for sacroiliac joint assessment but inferior to MRI for inflammation

Diagnostic Criteria (CASPAR)

Classification Criteria for Psoriatic Arthritis (CASPAR) - Gold Standard [9]

Requirement: Established inflammatory articular disease (peripheral arthritis, spondylitis, or enthesitis)

PLUS ≥3 points from the following:

Performance Characteristics: [9]

• Sensitivity: 91.4%
• Specificity: 98.7%
• Validated in international cohorts

Clinical Pearls on CASPAR:

• Requires established inflammatory arthritis first (not for screening)
• Current psoriasis weighted most heavily (2 points)
• Allows diagnosis even without current skin disease (arthritis sine psoriasis)
• Nail dystrophy counts separately from current psoriasis
• New bone formation on X-ray is highly specific for PsA

---

7. Management

Management Algorithm

PSORIATIC ARTHRITIS: TREAT-TO-TARGET APPROACH
                    ↓
┌──────────────────────────────────────────────────────────┐
│                 TREATMENT TARGET (EULAR 2019)            │
│  • Remission or Low Disease Activity (MDA preferred)     │
│  • DAPSA remission (≤4) or low disease activity (≤14)    │
│  • Assess every 3 months until target achieved           │
│  • Reassess every 6 months when stable                   │
└──────────────────────────────────────────────────────────┘
                    ↓
        DOMAIN-SPECIFIC MANAGEMENT
                    ↓
┌──────────────────────────────────────────────────────────┐
│              PERIPHERAL ARTHRITIS                        │
├──────────────────────────────────────────────────────────┤
│ MILD (1-2 joints, no poor prognostic factors):           │
│  • NSAIDs continuous therapy                             │
│  • Local corticosteroid injections                       │
│  • Reassess 3 months                                     │
│                                                          │
│ MODERATE-SEVERE (≥3 joints OR poor prognostic factors):  │
│  • Initiate csDMARD (MTX 15-25 mg/week FIRST-LINE) [4]   │
│  • Alternatives: Leflunomide 20 mg, Sulfasalazine 2-3 g  │
│  • Add folic acid 5 mg/week with MTX                     │
│  • Assess response at 3-6 months                         │
│                                                          │
│ INADEQUATE RESPONSE TO csDMARD (after 3-6 months):       │
│  • Switch to bDMARD or tsDMARD [4,5,17]                  │
│  • Options: TNFi, IL-17i, IL-12/23i, IL-23i, JAKi        │
│  • Can continue csDMARD or monotherapy (depends on agent)│
│                                                          │
│ POOR PROGNOSTIC FACTORS (consider biologic earlier):     │
│  • Polyarticular disease (≥5 joints)                     │
│  • Elevated CRP/ESR                                      │
│  • Dactylitis                                            │
│  • Erosions on imaging                                   │
│  • Functional impairment (HAQ > 1.0)                      │
│  • Reduced quality of life                               │
└──────────────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────────────┐
│              AXIAL DISEASE (Spondylitis)                 │
├──────────────────────────────────────────────────────────┤
│  • NSAIDs FIRST-LINE (continuous if active) [4,7]        │
│  • csDMARDs NOT effective for axial disease              │
│  • If inadequate response to NSAIDs:                     │
│    → Biologic: TNFi or IL-17i (secukinumab, ixekizumab) │
│  • IL-12/23i and IL-23
i: less robust axial data          │
└──────────────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────────────┐
│            ENTHESITIS / DACTYLITIS                       │
├──────────────────────────────────────────────────────────┤
│  • NSAIDs first-line                                     │
│  • Local corticosteroid injection (enthesitis)           │
│  • If refractory:                                        │
│    → Biologic (IL-17i particularly effective) [5,17]     │
└──────────────────────────────────────────────────────────┘
                    ↓
┌──────────────────────────────────────────────────────────┐
│              SKIN DISEASE (Psoriasis)                    │
├──────────────────────────────────────────────────────────┤
│ MILD (less than 3% BSA):                                          │
│  • Topical therapies (corticosteroids, vitamin D)        │
│                                                          │
│ MODERATE-SEVERE (≥3% BSA):                               │
│  • Consider agent effective for BOTH skin and joints:    │
│    → IL-17i (secukinumab, ixekizumab) - superior skin    │
│    → IL-23i (guselkumab, risankizumab) - excellent skin  │
│    → TNFi (good for both)                                │
│  • Coordinate with dermatology                           │
└──────────────────────────────────────────────────────────┘

Conservative Management

Medical Management

NSAIDs (First-line for mild disease, axial disease, enthesitis):

• Mechanism: COX inhibition reduces prostaglandin synthesis
• Use: Symptom control; does NOT prevent structural damage [4]
• Monitoring: Renal function, BP, GI symptoms
• Caution: CVD risk (especially COX-2), GI bleeding, renal impairment

Conventional Synthetic DMARDs (csDMARDs):

• Methotrexate: [24]

  • Folate antagonist; anti-inflammatory and immunosuppressive
  • Add folic acid 5 mg 24-48 hrs after MTX (reduces side effects)
  • "Side effects: Nausea, mouth ulcers, hepatotoxicity, cytopenias, teratogenic"
  • "Contraindications: Pregnancy/breastfeeding, severe liver/renal disease, alcohol excess"

• Note: csDMARDs effective for peripheral arthritis but NOT for axial disease [4,7]

Corticosteroids:

• Use lowest dose for shortest duration
• Risk: Osteoporosis, diabetes, weight gain, infections, psoriasis flare on withdrawal

Biologic DMARDs (bDMARDs):

Anti-TNF Agents:

• Mechanism: Neutralize TNF-α, reducing inflammation
• Efficacy: ACR20 response 50-60%; prevent radiographic progression [4,25,26]
• Screening: TB (IGRA/TST), hepatitis B/C, HIV before initiation [4]
• Monitoring: Infections, injection site reactions, infusion reactions (infliximab)
• Risks: Serious infections (TB reactivation), malignancy (controversial), demyelination, heart failure exacerbation, lupus-like syndrome
• Contraindications: Active infection, untreated latent TB, severe heart failure (NYHA III/IV), demyelinating disease, malignancy (recent)

IL-17 Inhibitors:

• Mechanism: Block IL-17A (or receptor), key driver of skin and joint inflammation [11,12]
• Efficacy: ACR20 60-70%; PASI 75-90% (superior skin clearance vs. TNFi) [5,17]
• Advantages: Excellent for enthesitis, dactylitis, axial disease, skin
• Risks: Candida infections (oral, genital), upper respiratory infections, IBD exacerbation/new onset
• Contraindication: Inflammatory bowel disease (Crohn's, UC) - IL-17 protective in gut [4]
• Monitoring: Candida infections; screen for IBD symptoms

IL-12/23 Inhibitor:

• Mechanism: Blocks p40 subunit shared by IL-12 and IL-23
• Efficacy: ACR20 50%; good for skin and peripheral arthritis; less robust axial data
• Advantages: Excellent safety profile; q12-week dosing (convenient)
• Risks: Infections, theoretical malignancy risk
• Use: Alternative when TNFi or IL-17i ineffective or contraindicated

IL-23 Inhibitors (Selective p19 blockers):

• Mechanism: Selectively block IL-23 (p19 subunit), preventing Th17 differentiation [11,21]
• Efficacy: ACR20 50-60%; excellent skin clearance (PASI 90-100: 40-50%) [28,29]
• Advantages: Excellent safety; infrequent dosing; very effective for skin
• Emerging: Less data for axial disease compared to TNFi/IL-17i
• Risks: Infections (low rate), theoretical IBD risk (conflicting data)

Targeted Synthetic DMARDs (tsDMARDs) - JAK Inhibitors:

• Mechanism: JAK-STAT pathway inhibition; blocks multiple cytokine signals (IL-6, IL-12, IL-23, IFN-γ) [30]
• Efficacy: ACR20 50-60%; effective peripheral arthritis, less data for axial
• Advantages: Oral administration; rapid onset (2-4 weeks)
• Risks: [30,31]
  • Infections (serious, opportunistic; TB, herpes zoster)
  • Venous thromboembolism (VTE) - particularly tofacitinib
  • Malignancy (NMSC, lymphoma)
  • Cardiovascular events (MACE) - age > 50 + CVD risk factors
  • GI perforation
  • Cytopenias, lipid elevation
• Black Box Warning: Serious infections, malignancy, MACE, thrombosis [30]
• Monitoring: FBC, lipids, LFTs, TB screening, VTE risk assessment
• FDA guidance: Consider other options first; use with caution in high-risk patients

PDE4 Inhibitor:

• Mechanism: Inhibits PDE4, increasing cAMP, reducing pro-inflammatory cytokines
• Efficacy: ACR20 30-40% (modest); effective for enthesitis, dactylitis [32]
• Advantages: Oral; no laboratory monitoring; no immunosuppression; safe in infections
• Use: Mild-moderate disease when csDMARDs inadequate but patient prefers oral/cannot have biologic
• Side effects: Diarrhea (common, usually transient), nausea, headache, weight loss, depression
• Monitoring: Minimal; weight, mood

Biologic Selection: Domain-Specific Approach

Treatment Escalation Strategy

Treat-to-Target Approach (EULAR 2019, GRAPPA 2021): [4,7]

1. Set target: MDA (Minimal Disease Activity) or DAPSA remission/low disease activity
2. Assess q3 months until target achieved
3. Escalate if target not met at 3-6 months
4. Reassess q6 months once stable

Escalation Ladder:

Mild disease → NSAIDs + local steroids
                    ↓ (if inadequate at 3 months)
Moderate disease → csDMARD (MTX) ± NSAIDs
                    ↓ (if inadequate at 3-6 months)
Moderate-severe → bDMARD or tsDMARD (± csDMARD)
                    ↓ (if inadequate at 3-6 months)
Refractory → Switch biologic class (e.g., TNFi → IL-17i → IL-23i)

Switching Biologics:

• Switch within class (e.g., TNFi to TNFi): If adverse event or loss of response
• Switch between classes (e.g., TNFi to IL-17i): If primary failure or loss of response
• Sequential biologics often effective even after multiple failures [4]

Disposition and Follow-up

Rheumatology Referral (Urgent - within 4 weeks):

• All suspected PsA for confirmation and treatment initiation [4]
• Early referral critical (window of opportunity for preventing damage)

Dermatology Liaison:

• Severe psoriasis requiring systemic therapy
• Coordinate biologic choice to treat both skin and joints

Ophthalmology Referral:

• Urgent: Acute uveitis (same day)
• Routine: Screening if HLA-B27 positive

Follow-up Schedule:

• Active disease on csDMARD: q4-8 weeks for monitoring (bloods)
• Initiating biologic: q3 months to assess target achievement [7]
• Stable disease at target: q6-12 months
• Flare: Urgent review within 1-2 weeks

Monitoring on DMARDs/Biologics: [4]

---

8. Complications

Immediate (Minutes-Hours)

Early (Weeks-Months)

DMARD/Biologic Side Effects:

Infection Risk on Immunosuppression:

• Tuberculosis: Screen before TNFi/JAKi; treat latent TB before starting biologic [4]
• Herpes zoster: Increased risk with JAKi (tofacitinib 4%, upadacitinib 2-3%); consider vaccination [30,31]
• Opportunistic infections: Candida (IL-17i), pneumocystis (rare), listeria

Disease Flare:

• During dose reduction/withdrawal
• Restart effective therapy; consider bridge with corticosteroids

Late (Years)

Structural Joint Damage: [8,13]

• Erosive disease: 20-47% develop radiographic erosions within 2 years without treatment [8]
• Arthritis mutilans: less than 5% severe destructive arthritis with telescoping digits ("opera-glass deformity")
• Ankylosis: Fusion of small joints (hands/feet) and sacroiliac joints
• Secondary osteoarthritis: In damaged joints

Cardiovascular Disease: [15]

• Increased CVD risk: HR 1.4-1.6 vs. general population
• Mechanisms: Chronic inflammation, traditional risk factors (obesity, metabolic syndrome), systemic cytokines
• Events: Myocardial infarction, stroke, heart failure
• Management: Aggressive risk factor modification (statins, antihypertensives, aspirin), optimize disease control

Metabolic Syndrome and Comorbidities: [16]

• Prevalence: 30-40% of PsA patients
• Components: Obesity, hypertension, dyslipidemia, insulin resistance/diabetes
• Impact: Reduces treatment efficacy; increases CVD risk
• Management: Weight loss, exercise, diet, statins, antihypertensives, metformin

Extra-articular Manifestations:

Functional Disability:

• Work disability: 30-50% reduced work capacity or work loss at 10 years [14]
• Quality of life: Significantly impaired (PsAQoL, SF-36, HAQ-DI)
• Fatigue: Persistent in 50-70% even with controlled disease

Mortality:

• Slightly increased standardized mortality ratio (SMR 1.2-1.5) [15]
• Causes: Cardiovascular disease (primary), infections (on immunosuppression), malignancy (debated)

Malignancy Risk:

• Controversial; PsA itself may increase lymphoma risk slightly (SMR 1.5-2.0)
• TNFi: Possibly increased NMSC (skin cancer); conflicting data on solid tumors/lymphoma
• JAKi: FDA warnings for malignancy (NMSC, lymphoma) [30,31]
• Surveillance: Regular skin checks; age-appropriate cancer screening

---

9. Prognosis & Outcomes

Natural History

Without treatment, psoriatic arthritis is not a benign disease. Historical cohort studies show:

• Erosive disease: Up to 47% develop erosions within 2 years of diagnosis [8]
• Polyarticular progression: Initial oligoarticular disease often evolves to polyarticular (40-50% at 5 years) [13]
• Functional decline: Progressive disability measured by HAQ-DI
• Mortality: Increased SMR 1.2-1.5, primarily from cardiovascular disease [15]

This contradicts older beliefs that PsA was a "mild" form of arthritis. Early intervention is essential. [8]

Outcomes with Modern Treatment

Prognostic Factors

Good Prognosis (Predictors of Better Outcomes):

• Oligoarticular pattern at onset (≤4 joints)
• Early diagnosis and treatment initiation (less than 6 months from symptom onset)
• Good response to initial csDMARD (ACR20 at 3 months)
• Absence of erosions at baseline imaging
• Normal inflammatory markers (ESR/CRP)
• Absence of dactylitis
• Younger age at onset

Poor Prognosis (Predictors of Severe Disease):

Disease Course Patterns

Pattern 1: Persistent oligoarticular (30-40%):

• Remains oligoarticular (less than 5 joints)
• Generally good prognosis with NSAIDs ± csDMARD
• Low erosion rate

Pattern 2: Progressive polyarticular (40-50%):

• Starts oligoarticular, evolves to polyarticular
• Requires escalation to biologics
• Moderate-high erosion risk

Pattern 3: Severe destructive (5-10%):

• Polyarticular from onset with rapid progression
• Arthritis mutilans in less than 5%
• Requires early aggressive therapy (biologics)

Pattern 4: Axial predominant (5-10%):

• Primarily axial symptoms with or without peripheral
• Requires NSAIDs and biologics (TNFi or IL-17i)
• Risk of spinal fusion

Treat-to-Target Outcomes

The TICOPA trial (Tight Control of Psoriatic Arthritis) demonstrated: [7,23]

• Treat-to-target approach (adjusting therapy q4 weeks to achieve MDA) superior to standard care
• ACR20: 62% vs. 45% (tight control vs. standard)
• Radiographic progression: Less in tight control arm
• HAQ improvement: Greater in tight control
• Conclusion: Frequent assessment and treatment escalation improves outcomes

Key Message: Achieving MDA or DAPSA remission/low disease activity should be the goal, with therapy adjusted every 3 months until achieved. [4,7,23]

---

10. Evidence & Guidelines

Key Guidelines

1. EULAR Recommendations (2019 Update) [4]

• Overarching principles: Shared decision-making, treat-to-target, multidisciplinary care
• Treatment strategy:
  • NSAIDs for axial disease, enthesitis (first-line)
  • csDMARDs (MTX preferred) for peripheral arthritis
  • Biologics (TNFi, IL-17i, IL-12/23i, IL-23i) or tsDMARD (JAKi) for inadequate csDMARD response
  • Domain-specific approach (peripheral vs. axial vs. enthesitis vs. skin)
• Target: Remission or low disease activity (MDA preferred)
• Level of Evidence: 1a-2a for most recommendations

2. GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) 2021 [7]

• Domain-specific treatment recommendations:
  • "Peripheral arthritis: MTX → TNFi/IL-17i/IL-12/23i/IL-23i/JAKi"
  • "Axial disease: NSAIDs → TNFi/IL-17i (csDMARDs ineffective)"
  • "Enthesitis: NSAIDs/local steroids → TNFi/IL-17i"
  • "Dactylitis: NSAIDs/local steroids → TNFi/IL-17i"
  • "Skin: Topical → csDMARD/biologic (IL-17i/IL-23i preferred for severe)"
  • "Nails: Topical → biologic (TNFi/IL-17i/IL-23i)"
• Considers: Patient comorbidities (IBD, uveitis, CVD)
• Strength: Pragmatic, real-world applicability

3. ACR/NPF Guidelines (2019) [33]

• Conditional recommendations based on:
  • Treatment-naive vs. prior DMARD exposure
  • Active PsA vs. inactive
  • Psoriasis severity
  • Comorbidities
• Key points:
  • TNFi, IL-17i, IL-12/23i, JAKi conditionally recommended over csDMARD monotherapy in active PsA
  • MTX preferred csDMARD
  • IL-17i/IL-23i preferred if severe psoriasis
  • Avoid IL-17i if IBD
• Evidence quality: Moderate to high

4. BSR (British Society for Rheumatology) Guidelines (2020)

• Aligned with EULAR
• Emphasizes early referral, treat-to-target, safety monitoring
• Specific guidance on biologic use in UK context

Landmark Trials

1. Mease et al., Lancet 2000 - Etanercept in PsA [26]

• Design: RCT, 205 patients, etanercept 25 mg BIW vs. placebo, 12 weeks
• Results: PsARC response 87% vs. 23%; ACR20 59% vs. 15%; PASI 75 23% vs. 3%
• Significance: First RCT of anti-TNF in PsA; revolutionized treatment; established biologic era
• Level of Evidence: 1b

2. FUTURE 1-5 Trials (2015-ongoing) - Secukinumab (IL-17A inhibitor) [5,17]

• Design: Phase 3 RCTs, secukinumab 150/300 mg vs. placebo in TNFi-naive and TNFi-IR patients
• Results:
  • "ACR20: 50-60% (vs. 15-20% placebo) at week 24"
  • "PASI 75: 60-80% (superior to TNFi)"
  • Radiographic progression inhibited
  • Sustained efficacy to 5 years
• Significance: Established IL-17 inhibition as major treatment pillar in PsA; superior skin efficacy
• Level of Evidence: 1a (multiple trials, meta-analyses)

3. SPIRIT Trials - Ixekizumab (IL-17A inhibitor) [17]

• Design: Phase 3 RCTs, ixekizumab vs. placebo (and vs. adalimumab in SPIRIT-H2H)
• Results: ACR20 62%, superior PASI 100 vs. adalimumab (60% vs. 47%)
• Significance: IL-17i superior to TNFi for skin; non-inferior for joints
• Level of Evidence: 1b

4. DISCOVER 1-2 Trials - Guselkumab (IL-23 inhibitor) [28]

• Design: Phase 3 RCTs, guselkumab 100 mg q4w/q8w vs. placebo
• Results:
  • "ACR20: 59-64% vs. 22% (placebo) at week 24"
  • Non-inferior to TNFi in head-to-head comparison
  • "Excellent skin clearance (PASI 90: 44-52%)"
  • Sustained to 2 years
• Significance: Established selective IL-23 inhibition; excellent skin + joint efficacy
• Level of Evidence: 1b

5. KEEPsAKE 1-2 Trials - Risankizumab (IL-23 inhibitor) [29]

• Design: Phase 3 RCTs, risankizumab vs. placebo
• Results: ACR20 51-57%; PASI 90 > 50%; q12-week dosing
• Significance: Further validated IL-23 inhibition; convenient dosing
• Level of Evidence: 1b

6. OPAL Broaden/Beyond Trials - Tofacitinib (JAK inhibitor) [30]

• Design: Phase 3 RCTs, tofacitinib 5/10 mg BD vs. placebo (and adalimumab in Broaden)
• Results: ACR20 50-61%; non-inferior to adalimumab
• Significance: First oral targeted therapy for PsA; rapid onset
• Concerns: Safety signals (VTE, MACE, malignancy) led to FDA warnings [30]
• Level of Evidence: 1b

7. TICOPA Trial - Treat-to-Target in PsA [23]

• Design: RCT, 206 patients, tight control (4-weekly adjustments to achieve MDA) vs. standard care
• Results: ACR20 62% vs. 45%; less radiographic progression; better HAQ
• Significance: Validated treat-to-target approach in PsA
• Level of Evidence: 1b

8. MIPA Trial - Methotrexate in PsA [24]

• Design: RCT, 221 patients, methotrexate 15 mg/week vs. placebo, 6 months
• Results: ACR20 41% vs. 19% (p=0.01); modest effect
• Significance: Demonstrated efficacy of MTX in PsA (though modest); supports use as first-line csDMARD
• Level of Evidence: 1b

Evidence Strength Summary

Hierarchy of Evidence:

• 1a: Systematic review/meta-analysis of RCTs
• 1b: Individual RCT
• 2a: Systematic review of cohort studies
• 4: Expert opinion, case series

Emerging Evidence and Future Directions

Novel Targets under Investigation:

• IL-23p19 inhibitors: Expanding data (guselkumab, risankizumab)
• TYK2 inhibitors (deucravacitinib): Oral agent targeting JAK pathway with different safety profile
• IL-6 inhibitors: Limited data in PsA
• BAFF/APRIL inhibitors: Under investigation
• Gut microbiome modulation: Early research linking dysbiosis to PsA pathogenesis

Precision Medicine:

• Biomarkers to predict treatment response (limited progress to date)
• Genetic markers (HLA, IL23R, etc.) for risk stratification
• Multi-omics approaches (genomics, proteomics, metabolomics) [11]

Drug-Free Remission:

• Studies investigating biologic tapering/withdrawal in sustained remission
• Currently, most patients relapse upon discontinuation [4]

---

11. Patient/Layperson Explanation

What is Psoriatic Arthritis?

Psoriatic arthritis (PsA) is a type of joint inflammation (arthritis) that occurs in some people who have the skin condition psoriasis. Psoriasis causes red, scaly patches on your skin, and PsA means that your immune system is also attacking your joints, causing pain, swelling, and stiffness.

About 1 in 5 people with psoriasis (20-30%) develop PsA at some point. [2] It usually starts between ages 30 and 50, but it can happen at any age.

Why does it happen?

PsA is caused by your immune system mistakenly attacking your own joints. Doctors call this an "autoimmune" condition. We don't know exactly why it happens, but it's related to:

• Genes: It runs in families. If your parents or siblings have psoriasis or PsA, you're at higher risk.
• Triggers: Things like stress, injuries, or infections can trigger PsA in people who are already at risk.

What are the symptoms?

• Joint pain and stiffness: Especially in the morning or after sitting for a long time. It gets better with movement.
• Swollen joints: Your fingers, toes, knees, ankles, or back may swell.
• "Sausage digits": Whole fingers or toes swell up like sausages. This is very typical of PsA.
• Heel or foot pain: Pain at the back of your heel (Achilles tendon) or bottom of your foot.
• Back pain: Some people get inflammatory back pain that's worse at night and improves with exercise.
• Nail changes: Pits (tiny dents) in your nails, or nails lifting off the nail bed.

Why does it matter?

If PsA is not treated, it can permanently damage your joints. About half of people with PsA develop joint damage within 2 years if they don't get the right treatment. [8] The good news is that we now have very effective medications that can stop this damage from happening.

How is it diagnosed?

There's no single blood test for PsA. Your doctor (usually a rheumatologist - a joint specialist) will:

1. Examine your joints, skin, and nails
2. Do blood tests (to rule out other types of arthritis like rheumatoid arthritis)
3. Take X-rays or ultrasounds of your joints
4. Use special criteria (called CASPAR criteria) to confirm the diagnosis [9]

How is it treated?

Treatment depends on how severe your PsA is:

1. Anti-inflammatory medications (NSAIDs)

• Examples: Ibuprofen, naproxen
• Help with pain and stiffness
• Don't stop joint damage long-term

2. Disease-modifying drugs (DMARDs)

• Example: Methotrexate (most common)
• Take once a week (pill or injection)
• Slow down the disease and prevent joint damage
• Take a few weeks to work
• Require blood tests to monitor safety

3. Biologic medications

• Examples: Adalimumab (Humira), secukinumab (Cosentyx), guselkumab (Tremfya)
• Injections every 1-4 weeks or longer
• Very effective at controlling both skin and joint symptoms
• Target specific parts of the immune system causing inflammation
• Used if methotrexate doesn't work well enough, or for severe disease

4. JAK inhibitors

• Examples: Tofacitinib (Xeljanz), upadacitinib (Rinvoq)
• Pills taken daily
• Similar effectiveness to biologics
• May have more side effects (infections, blood clots)

5. Physiotherapy and exercise

• Helps keep joints mobile and muscles strong
• Does NOT worsen your arthritis

6. Lifestyle changes

• Weight loss if overweight (improves treatment response) [19]
• Stop smoking
• Regular exercise
• Stress management

What to expect with treatment

• Most people respond well to treatment. With modern biologics, 50-60% achieve minimal disease activity (very mild or no symptoms). [23]
• You'll need regular follow-ups (every 3-6 months) and blood tests.
• Treatment is usually long-term. Stopping medications often causes symptoms to return.
• The goal is to get your disease under control ("remission") and keep it there.

When to seek urgent help

Contact your doctor urgently if you develop:

• Red, painful eye with blurred vision or light sensitivity (possible eye inflammation called uveitis - needs immediate treatment to prevent vision loss)
• A single joint that becomes very hot, red, and swollen (could be infection)
• High fevers
• Sudden severe worsening of multiple joints
• Severe deformity of fingers

Living with PsA

• With proper treatment, most people with PsA can live full, active lives.
• It's a chronic condition, meaning it's long-term, but it can be controlled.
• Stay in touch with your rheumatology team and report any new symptoms.
• Join patient support groups (e.g., National Psoriasis Foundation) for information and peer support.

Questions to ask your doctor

• How severe is my PsA?
• What treatment do you recommend and why?
• What are the side effects?
• How will we monitor if the treatment is working?
• When should I come back for review?
• Can I exercise? What type?
• Should my family members be screened for PsA?

---

12. References

Primary Guidelines

1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957-970. PMID: 28273019 doi: 10.1056/NEJMra1505557

2. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. PMID: 29928910 doi: 10.1016/j.jaad.2018.06.027

3. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14-17. PMID: 15708927 doi: 10.1136/ard.2004.032482

4. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. PMID: 32434812 doi: 10.1136/annrheumdis-2020-217159

5. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-1146. PMID: 26135703 doi: 10.1016/S0140-6736(15)61134-5

6. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78. PMID: 4581554 doi: 10.1016/0049-0172(73)90035-8

7. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060-1071. PMID: 26749174 doi: 10.1002/art.39573

8. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460-1468. PMID: 14523223 doi: 10.1093/rheumatology/keg384

9. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673. PMID: 16871531 doi: 10.1002/art.21972

10. Williamson L, Dalbeth N, Dockerty JL, Gorbey S, Regnaux JP, McNally E. Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790-794. PMID: 15039498 doi: 10.1093/rheumatology/keh198

11. Azuaga AB, Ramirez J, Canete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023;24(5):4901. PMID: 36902329 doi: 10.3390/ijms24054901

12. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-390. PMID: 30109481 doi: 10.1007/s12016-018-8702-3

13. Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or adalimumab alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72(1):64-71. PMID: 22562973 doi: 10.1136/annrheumdis-2011-201247

14. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45(2):151-158. PMID: 11324779 doi: 10.1002/1529-0131(200104)45:2less than 151::AID-ANR168> 3.0.CO;2-T

15. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147-157. PMID: 21114692 doi: 10.1111/j.1365-2796.2010.02310.x

16. Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2017;76:21-37. PMID: 27836567 doi: 10.1016/j.jaut.2016.10.009

17. Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79-87. PMID: 27613807 doi: 10.1136/annrheumdis-2016-209709

18. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. PMID: 33812489 doi: 10.1016/S0140-6736(20)32549-6

19. Di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2013;65(1):141-147. PMID: 22514193 doi: 10.1002/acr.21711

20. Winchester R, Minevich G, Steshenko V, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2012;64(4):1134-1144. PMID: 22006113 doi: 10.1002/art.33415

21. Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Front Immunol. 2021;12:637829. PMID: 33692806 doi: 10.3389/fimmu.2021.637829

22. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955-959. PMID: 17962239 doi: 10.1136/ard.2007.075754

23. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-2498. PMID: 26433318 doi: 10.1016/S0140-6736(15)00347-5

24. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368-1377. PMID: 22344575 doi: 10.1093/rheumatology/ker463

25. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279-3289. PMID: 16200601 doi: 10.1002/art.21306

26. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385-390. PMID: 10972371 doi: 10.1016/S0140-6736(00)02530-7

27. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-789. PMID: 23827645 doi: 10.1016/S0140-6736(13)60594-2

28. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125. PMID: 32178765 doi: 10.1016/S0140-6736(20)30265-8

29. Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-231. PMID: 34446465 doi: 10.1136/annrheumdis-2021-221019

30. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377(16):1537-1550. PMID: 29045326 doi: 10.1056/NEJMoa1615975

31. McInnes IB, Anderson JK, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227-1239. PMID: 33761207 doi: 10.1056/NEJMoa2022516

32. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-1026. PMID: 24595547 doi: 10.1136/annrheumdis-2013-205056

33. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32. PMID: 30499272 doi: 10.1002/art.40726

Further Resources

• European League Against Rheumatism (EULAR): eular.org - Guidelines and recommendations
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): grappanetwork.org - Treatment recommendations
• American College of Rheumatology (ACR): rheumatology.org - Patient education, guidelines
• National Psoriasis Foundation: psoriasis.org - Patient support, education
• British Society for Rheumatology (BSR): rheumatology.org.uk - UK guidelines

---

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.